about
Venous thromboembolic diseaseDirect-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine PhysiciansReversal of oral anticoagulationPharmacology of anticoagulants used in the treatment of venous thromboembolismProthrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trialSelecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Correction of coagulopathy for percutaneous interventions.Polyphosphate as a general procoagulant agent.Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathyNanoparticle-allergen complexes for allergen immunotherapy.Prothrombin complex concentrates: an update.Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery.Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.Prothrombin complex concentrates utility for warfarin-associated hemorrhage.Reversal of warfarin-induced hemorrhage in the emergency department.The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulantsDelayed-type heparin allergy: diagnostic procedures and treatment alternatives-a case series including 15 patients.Surfen, a small molecule antagonist of heparan sulfateCauses and consequences of critical bleeding and mechanisms of blood coagulation.Proteomics: applications in transfusion medicine.Primary prophylaxis of venous thromboembolism in surgical patients.Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice.Clinical use and the Italian demand for prothrombin complex concentratesProthrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation.Anticoagulant and antithrombotic drugs in pregnancy: what are the anesthetic implications for labor and cesarean delivery?The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy.Treatment of warfarin-associated coagulopathy with vitamin K.Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.Acute gastrointestinal bleeding after percutaneous coronary intervention.Acute stroke management in patients taking dabigatran.Emergency neurological life support: intracerebral hemorrhage.New oral anticoagulants in non-valvular atrial fibrillation.Emergency Neurological Life Support: Intracerebral Hemorrhage.A New Generation of Antiplatelet, and Anticoagulant Medication and the Implications for the Dental Surgeon.Use of Molecular Dynamics for the Refinement of an Electrostatic Model for the In Silico Design of a Polymer Antidote for the Anticoagulant Fondaparinux.The epidemic of pre-injury oral antiplatelet and anticoagulant use.Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA.Newer antithrombotic drugsRecommendations for the use of antithrombin concentrates and prothrombin complex concentratesErratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism.
P2860
Q24631121-F6742E14-EF68-4F6A-BAEB-A057A2D7C797Q26746917-0FED543C-4C1D-4C6A-A7EC-562743CB797AQ26827835-7E8BEE85-9196-4CBF-BCA8-BBFB52E01422Q28078967-AB40EF18-E8EC-45E4-AC61-7219449AB37DQ28265484-270338D0-272E-4579-B227-2029ECA90BB1Q30438893-BC769800-80A7-4B5D-9721-29E4288E091EQ33401040-559E9346-3804-4F98-874C-26CCDC32C43EQ33724794-6A9500E8-1ACD-4833-B073-08E2C18B3E36Q33735132-C2CBF8DC-084F-4DC4-AED2-EE00DA915786Q33834985-2D4097BE-152F-46C6-89C3-68D25C5D494FQ34003474-99888CEB-F1E7-47E6-8779-EE24351F6596Q35078253-919CFC18-97AC-4CEC-AA76-D9B35FEDBC1BQ35156759-3CD10E7B-CAD3-4C13-BBA6-EC4663D9F56DQ35481316-C597C47E-E538-4ECF-918A-5BBAF114CEE8Q35608280-64103EB2-651B-485F-A9D9-3EFB6A274270Q36396649-644EBF99-1571-4E52-974B-BBB8F8889E52Q36834381-E9123BB1-BE56-4FF1-94D9-28FE5523191CQ36861535-19BE8C61-FA49-4AA5-87EF-D46BFB28CEA4Q36920715-AF9BCF64-1C12-45D2-922E-B4720BF0DCEAQ37062388-DCEC54B9-661B-474E-83A8-AB4702464505Q37122818-1C3D2C0F-F633-4039-945E-2C51CFDA8508Q37210021-EC57AB9C-C6F2-448D-B0A1-851F878D8223Q37370338-81094AB7-135A-4BA6-B1DF-0A26A3BDCD2BQ37733748-87256581-4DC3-49AB-877E-37AE8317CB25Q37766083-F5F352D0-333C-40B3-AF03-F484A291C372Q37873969-A5574768-27DD-45DB-B020-2B4583D0700EQ37955232-A4112907-1A0E-43E8-9F73-5C43AB4D7685Q37961830-FF13BC2C-EABC-4F18-88A7-E2D067AF5D8AQ37989162-D9E2D889-5680-4442-BF77-68F4BC64E448Q38005465-82FB9CDB-F9A8-4F4D-925F-570DBBCAC125Q38042353-493DCE72-9E9F-4C35-9CE6-DDBF9DD7C127Q38105041-F6770403-FFBB-4F66-8DA7-2FFEA7F1E78CQ38599754-DDBEA276-1CF1-42DB-BD2E-65CEDF4EA93FQ38691618-5A6F05C9-C943-44B1-BE27-895AD3988B67Q38840652-C3F7158D-20AA-4291-A592-77F555B617B0Q38915687-6E400B33-22A9-419F-AB10-2B0C076B995AQ39051903-8831F932-E4E7-40A1-8166-193C1CE7F010Q41862291-EC5695DF-CF4C-477E-AC6B-DD1D3CF1B686Q42096335-1119B853-B8D7-4703-AC85-3EF7F8F0569CQ42387444-33A88D66-D92D-4538-9A0F-BC6A64C56938
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Anticoagulants and their reversal.
@ast
Anticoagulants and their reversal.
@en
type
label
Anticoagulants and their reversal.
@ast
Anticoagulants and their reversal.
@en
prefLabel
Anticoagulants and their reversal.
@ast
Anticoagulants and their reversal.
@en
P1476
Anticoagulants and their reversal.
@en
P2093
Nick R Bijsterveld
Sam Schulman
P356
10.1016/J.TMRV.2006.08.002
P577
2007-01-01T00:00:00Z